PE20000042A1 - Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas - Google Patents
Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativasInfo
- Publication number
- PE20000042A1 PE20000042A1 PE1998001263A PE00126398A PE20000042A1 PE 20000042 A1 PE20000042 A1 PE 20000042A1 PE 1998001263 A PE1998001263 A PE 1998001263A PE 00126398 A PE00126398 A PE 00126398A PE 20000042 A1 PE20000042 A1 PE 20000042A1
- Authority
- PE
- Peru
- Prior art keywords
- cancer
- myeloid
- treatment
- proliferative diseases
- antineoplastic agent
- Prior art date
Links
- 229940034982 antineoplastic agent Drugs 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 229940123468 Transferase inhibitor Drugs 0.000 title 1
- 238000001959 radiotherapy Methods 0.000 title 1
- 239000003558 transferase inhibitor Substances 0.000 title 1
- -1 CITARABIN Chemical compound 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 108010092160 Dactinomycin Proteins 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 abstract 2
- 229960000640 dactinomycin Drugs 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 abstract 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 abstract 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 abstract 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- 108010006654 Bleomycin Proteins 0.000 abstract 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 abstract 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- 206010024291 Leukaemias acute myeloid Diseases 0.000 abstract 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 229940122803 Vinca alkaloid Drugs 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229960001561 bleomycin Drugs 0.000 abstract 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 abstract 1
- 229960002092 busulfan Drugs 0.000 abstract 1
- 229960005243 carmustine Drugs 0.000 abstract 1
- 239000012829 chemotherapy agent Substances 0.000 abstract 1
- 229960004630 chlorambucil Drugs 0.000 abstract 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229960003901 dacarbazine Drugs 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 229960000975 daunorubicin Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 abstract 1
- 229960000961 floxuridine Drugs 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 230000003325 follicular Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 229960001101 ifosfamide Drugs 0.000 abstract 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 abstract 1
- 229960002247 lomustine Drugs 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 229960004961 mechlorethamine Drugs 0.000 abstract 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 229960001924 melphalan Drugs 0.000 abstract 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 abstract 1
- 229960001428 mercaptopurine Drugs 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 abstract 1
- 229960002340 pentostatin Drugs 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229960000952 pipobroman Drugs 0.000 abstract 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 abstract 1
- 229960001052 streptozocin Drugs 0.000 abstract 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 abstract 1
- 229960004964 temozolomide Drugs 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
- 229950001353 tretamine Drugs 0.000 abstract 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 abstract 1
- 229960001055 uracil mustard Drugs 0.000 abstract 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 abstract 1
- 229960003048 vinblastine Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1
- 229960004528 vincristine Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99602797A | 1997-12-22 | 1997-12-22 | |
| US14352998A | 1998-08-28 | 1998-08-28 | |
| US18196998A | 1998-10-29 | 1998-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000042A1 true PE20000042A1 (es) | 2000-02-17 |
Family
ID=27385940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998001263A PE20000042A1 (es) | 1997-12-22 | 1998-12-21 | Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1041985B1 (https=) |
| JP (1) | JP4502503B2 (https=) |
| KR (1) | KR100700907B1 (https=) |
| CN (1) | CN1129431C (https=) |
| AR (1) | AR017440A1 (https=) |
| AT (1) | ATE317697T1 (https=) |
| AU (1) | AU756762B2 (https=) |
| BR (1) | BR9814419A (https=) |
| CA (1) | CA2315693C (https=) |
| CL (1) | CL2007001889A1 (https=) |
| CO (1) | CO5080764A1 (https=) |
| CZ (1) | CZ298511B6 (https=) |
| DE (1) | DE69833509T2 (https=) |
| DK (1) | DK1041985T3 (https=) |
| ES (1) | ES2255196T3 (https=) |
| HU (1) | HUP0102473A3 (https=) |
| IL (1) | IL136462A0 (https=) |
| MY (1) | MY137303A (https=) |
| NO (1) | NO326832B1 (https=) |
| NZ (1) | NZ504928A (https=) |
| PE (1) | PE20000042A1 (https=) |
| PT (1) | PT1041985E (https=) |
| SK (1) | SK285584B6 (https=) |
| TW (1) | TW581763B (https=) |
| WO (1) | WO1999032114A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2787327B1 (fr) * | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
| CZ20021550A3 (cs) * | 1999-11-09 | 2003-02-12 | Societe De Conseils De Recherches Et D'application | Produkt zahrnující inhibitor transdukce signálů heterotrimerického G proteinu kombinovaný s jiným protirakovinným činidlem pro terapeutické použití v léčbě rakoviny |
| WO2001045740A2 (en) * | 1999-12-22 | 2001-06-28 | The Government Of The United States, Department Of Health And Human Services | Compositions and methods for treatment of breast cancer |
| US20030027808A1 (en) * | 2000-02-29 | 2003-02-06 | Palmer Peter Albert | Farnesyl protein transferase inhibitor combinations with platinum compounds |
| EP1261343A2 (en) * | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| US20030078281A1 (en) * | 2000-02-29 | 2003-04-24 | Rybak Mary Ellen Margaret | Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents |
| EP1267871A2 (en) * | 2000-02-29 | 2003-01-02 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| WO2001064196A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| AU2001244167A1 (en) * | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| WO2002056884A2 (en) * | 2001-01-22 | 2002-07-25 | Schering Corporation | Treatment of malaria with farnesyl protein transferase inhibitors |
| JP4969016B2 (ja) * | 2001-02-15 | 2012-07-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物 |
| CN1617755A (zh) * | 2001-11-30 | 2005-05-18 | 先灵公司 | 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 |
| CA2468996A1 (en) * | 2001-12-03 | 2003-06-12 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| WO2008022535A1 (fr) * | 2006-08-09 | 2008-02-28 | Tian Jin Tasly Group Co., Ltd. | Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique |
| CN105198758A (zh) * | 2015-09-22 | 2015-12-30 | 湖南大学 | 一种高纯度(z)-他莫昔酚的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047246A (en) * | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| WO1992011034A1 (en) * | 1990-12-18 | 1992-07-09 | The Wellcome Foundation Limited | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
| JP2767176B2 (ja) * | 1992-12-15 | 1998-06-18 | 大塚製薬株式会社 | 抗癌剤 |
| US5637688A (en) * | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
| DE69635114T2 (de) * | 1995-08-09 | 2006-03-02 | Banyu Pharmaceutical Co., Ltd. | Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids |
| IL125062A (en) * | 1995-12-22 | 2003-11-23 | Schering Corp | Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases |
| CN1304058C (zh) * | 1996-03-12 | 2007-03-14 | Pg－Txl有限公司 | 水溶性紫杉醇产品 |
| EP0959883A4 (en) * | 1996-04-03 | 2001-05-09 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| US20020034725A1 (en) * | 1996-04-15 | 2002-03-21 | W. Gillies Mckenna | Sensitization of cells to radiation and and chemotherapy |
| CA2251955A1 (en) * | 1996-04-18 | 1997-10-23 | Nancy E. Kohl | A method of treating cancer |
| EP0934270A1 (en) * | 1996-05-30 | 1999-08-11 | Merck & Co., Inc. | A method of treating cancer |
| US6337992B1 (en) * | 1997-01-29 | 2002-01-08 | Philips Medical Systems Technologies Ltd. | Predictive bolus tracking |
| IL131447A0 (en) * | 1997-02-18 | 2001-01-28 | Canji Inc | Combined tumor supressor gene therapy and chemotherapy in the treatment of neoplasms |
-
1998
- 1998-12-21 DK DK98963829T patent/DK1041985T3/da active
- 1998-12-21 PE PE1998001263A patent/PE20000042A1/es not_active Application Discontinuation
- 1998-12-21 SK SK898-2000A patent/SK285584B6/sk not_active IP Right Cessation
- 1998-12-21 EP EP98963829A patent/EP1041985B1/en not_active Expired - Lifetime
- 1998-12-21 AR ARP980106565A patent/AR017440A1/es unknown
- 1998-12-21 HU HU0102473A patent/HUP0102473A3/hu unknown
- 1998-12-21 KR KR1020007006938A patent/KR100700907B1/ko not_active Expired - Fee Related
- 1998-12-21 DE DE69833509T patent/DE69833509T2/de not_active Expired - Lifetime
- 1998-12-21 CA CA2315693A patent/CA2315693C/en not_active Expired - Fee Related
- 1998-12-21 TW TW087121355A patent/TW581763B/zh not_active IP Right Cessation
- 1998-12-21 AU AU19072/99A patent/AU756762B2/en not_active Ceased
- 1998-12-21 WO PCT/US1998/026224 patent/WO1999032114A1/en not_active Ceased
- 1998-12-21 CN CN98813742A patent/CN1129431C/zh not_active Expired - Fee Related
- 1998-12-21 AT AT98963829T patent/ATE317697T1/de not_active IP Right Cessation
- 1998-12-21 MY MYPI98005809A patent/MY137303A/en unknown
- 1998-12-21 NZ NZ504928A patent/NZ504928A/xx unknown
- 1998-12-21 CZ CZ20002236A patent/CZ298511B6/cs not_active IP Right Cessation
- 1998-12-21 CO CO98075842A patent/CO5080764A1/es unknown
- 1998-12-21 ES ES98963829T patent/ES2255196T3/es not_active Expired - Lifetime
- 1998-12-21 PT PT98963829T patent/PT1041985E/pt unknown
- 1998-12-21 JP JP2000525105A patent/JP4502503B2/ja not_active Expired - Fee Related
- 1998-12-21 IL IL13646298A patent/IL136462A0/xx unknown
- 1998-12-21 BR BR9814419-7A patent/BR9814419A/pt not_active Application Discontinuation
-
2000
- 2000-06-21 NO NO20003229A patent/NO326832B1/no not_active IP Right Cessation
-
2007
- 2007-06-27 CL CL2007001889A patent/CL2007001889A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000042A1 (es) | Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas | |
| ES2118160T3 (es) | Compuestos de azol, su produccion y su uso. | |
| PE20010025A1 (es) | Uso de un inhibidor de fpt y un inhibidor de la via de senalizacion ras adicional para inducir la muerte de celulas cancerosas y la regresion de tumores | |
| GEP20063799B (en) | Tropane derivatives useful in therapy | |
| MY131126A (en) | Sulfonamides | |
| ES2170252T3 (es) | Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde. | |
| ES2168737T3 (es) | Inhibidores de la oxido nitrico sintasa. | |
| AR020250A1 (es) | Compueto de isoxazolinona, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| DE69931925D1 (de) | 2-chinolonen enthaltende arzneimittel | |
| SE9704709D0 (sv) | Pharmaceutically active compounds | |
| ES2170102T3 (es) | Aminociclohexilesteres y utilizacion de los mismos. | |
| DE69925133D1 (de) | Pyrrolobenzodiazepine | |
| NO941378L (no) | Ikke-peptidyl-integrininhibitorer med spesifisitet for GPIIbIIIa-reseptoren | |
| YU63699A (sh) | Preparati za tretiranje i prevenciju arterijske tromboze i korišćenje inhibitora faktora xa samog ili u kombinaciji sa plateletnim antiagregacionim agensom | |
| UY24006A1 (es) | Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol. | |
| MXPA02012659A (es) | Derivados de pirazindiona condensados. | |
| AR010050A1 (es) | COMPUESTO TRICíCLICO SUSTITUIDO, COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE Y USO PARA FABRICAR UN MEDICAMENTO PARA INHIBIR SELECTIVAMENTE SPLA2 | |
| ES2162825T3 (es) | Derivados de piperazina. | |
| DE60016460D1 (de) | Verwendungen und zusammenstellungen von nitratestern als sedativa | |
| ATE137791T1 (de) | Cyanoacrylat-klebstoffe, die eine chinoide verbindung als polymerstabilisierungsmittel enthalten | |
| ATE153665T1 (de) | Tricyclische inhibitoren von gp ii b iii a rezeptoren | |
| AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
| MXPA03002909A (es) | Compuestos quimicos. | |
| CO5060424A1 (es) | Nuevos 1h-indazoles 1,5 y 3-0 sustituidos con efecto antias- matico, antialergico, antiinflamatorio, inmunomodulador y neuroprotector, procedimientos para su elaboracion y su aplicacion como medicamentos | |
| TR199800813T2 (xx) | Nitrik oksit sintaz�n�n �nleyicileri olarak amidin, isot�re t�revleri. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |